NCT06567899Not yet recruiting
Mechanistic Underpinnings of Preeclampsia
Source: ClinicalTrials.gov · Last updated 26 Nov 2025
Brief summary (registry, in English)
Preeclampsia is a dreadful disease with significant morbidity and mortality. Despite decades of research, we still need a proper diagnostic test or therapeutic option to treat this disorder. The proposed study will determine the diagnostic value of PBMC-secreted sFlt1 and determine the molecular mechanisms involved in its secretion. The molecular mechanisms can be novel therapeutic targets to treat this disorder.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 29 May 2024
- Start date
- 25 Jul 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- University of Arizona
- NCT number
- NCT06567899
What you commit to
- Study type: Observational
- Planned participants: 500
- From 25 Jul 2026 to the primary completion date, 31 Dec 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Healthy Adults:
- Healthy non-pregnant with previous normal pregnant women
- Non-Health Adults:
- Patients will be admitted with the diagnosis of preeclampsia according to the internationally accepted definition of preeclampsia: Blood pressure measurement of 140/90 mm Hg or an increase of 30 mm Hg systolic or 15 mm Hg diastolic over baseline values on at least two occasions, six or more hours apart and proteinuria; 300 mg/24 hour after 20th week of gestation.
- Pregnant Women:
- Groups 3 - 6 will include pregnant women at different trimesters.
- Criteria common to all groups:
- The study will be conducted only in females aged 18 or above.
- Patients in all the groups will be matched for age, which will be 18 or above.
- Women will be matched for body mass index; criteria for normal body mass index will be used based on the Center for Disease Control and Prevention Guidelines.
- Patients with premature rupture of the membrane, non-preeclamptic preterm labor, IUGR, placental abruption, twin? Any other complications during the pregnancy will be excluded from the study.
- Patients with any evidence of genetic or non-genetic malformations of the fetus will be excluded from the study.
- The study will be conducted on women who are non-smokers and do not consume alcohol or recreational drugs.
- The study will be conducted only on primigravida females to minimize phenotyping variability.
- The women with a known history of any chronic disorder, including but not limited to hypertension, diabetes, pulmonary, renal, cardiac, or cerebrovascular disorders, will be excluded from the studies.
Age in the registry: 18 years to - · Sex: Female · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.